Navigation Links
OncoMed Pharmaceuticals Completes Series B Financing
Date:11/4/2008

ors. OMP-21M18 targets a major cancer stem cell pathway, and is a part of OncoMed's collaboration with GlaxoSmithKline. The Phase I clinical trial is designed to evaluate the safety of escalating doses of OMP-21M18 in patients with solid tumors who have received previous treatment. Pharmacokinetics and initial indications of efficacy will also be assessed. OMP-21M18 is the first anti-cancer stem cell antibody against this novel target critical to cancer stem cells growth and development.

Cancer stem cells, a small subset of cells found in tumors, have the capacity to self-renew and differentiate, initiate and drive tumor growth, recurrence and metastasis. Also termed "tumor-initiating cells", these cells were discovered by OncoMed's scientific founders in breast cancer and have subsequently been identified in many other types of solid tumors including: colon, head and neck, lung, prostate, glioblastoma and pancreatic. Cancer stem cells appear to be preferentially resistant to both standard chemotherapy and radiotherapy. OncoMed's strategy is to improve cancer treatment by specifically targeting the key biologic pathways critical for the activity and survival of cancer stem cells. OncoMed's antibodies targeting cancer stem cell proteins have the potential to be developed against a range of solid tumor types such as pancreatic, breast, colorectal and lung cancers.

In conjunction with the financing, Denise Pollard-Knight, Ph.D., Managing Director of Nomura Phase4 Ventures, will join OncoMed's Board of Directors.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastases. A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal a
'/>"/>

SOURCE OncoMed Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
2. Genesis Pharmaceuticals Launches New Corporate Website
3. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
4. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
5. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
6. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
7. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
9. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
11. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... at USC have developed a new microscopy technology ... living animals at higher-than-ever resolution. , Dubbed "Complementation ... imaging resolutions that are an order of magnitude ... into the behavior of biomolecules at the nanometer ... 18 by Nature Communications , the researchers ...
(Date:9/18/2014)... MX (PRWEB) September 18, 2014 September ... Mexico City, MX. ASEA is the manufacturer of the ... the skin care product, RENU28. , The Mexico ... Vice President Duvan Botero, and ASEA Field Leader Shawn ... holds a PhD in Atomic/Medical Physics from the University ...
(Date:9/17/2014)... - Oncothyreon Inc. (NASDAQ: ONTY ) today ... of its Common Stock and Series A Convertible Preferred ... Series A Convertible Preferred Stock is non-voting and convertible ... will be prohibited if, as a result, the holder ... of the Common Stock then outstanding. As part of ...
(Date:9/17/2014)... 17, 2014 A biodegradable polymer ... such as bacteria, fungi, and algae into smaller ... biomass, inorganic compounds, carbon dioxide, and humus in ... base and improved costs, biodegradable polymers are proving ... alternative to conventional polymers. Primary factors that are ...
Breaking Biology Technology:Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3
... ... rolled out PatentSafe, protecting their forensic results and allowing their scientists to collate all ... ... Research Systems is pleased to announce that DNalysis have implemented PatentSafe to safeguard their ...
... , , , ... /PRNewswire-Asia/ -- 3SBio Inc. ( SSRX),("3SBio" or "the Company"), a ... products, today announced its unaudited financial results,for the fourth quarter and full ... Full Year 2009 Financial Highlights:, -- Total net revenues ...
... process that produces both n-type and p-type doping ... the promising material for future electronic devices. ... increase conductivity in graphene nanoribbons used for interconnects. ... to graphene and then exposing it to electron-beam ...
Cached Biology Technology:Independent Forensics Company DNalysis Implement Amphora's PatentSafe Solution to Preserve and Secure Findings 2Independent Forensics Company DNalysis Implement Amphora's PatentSafe Solution to Preserve and Secure Findings 33SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 23SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 33SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 43SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 53SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 63SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 73SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 83SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 93SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 103SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 113SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 123SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 133SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 143SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 153SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 163SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 173SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 183SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 193SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 203SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 213SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 223SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 233SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 243SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 253SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 26Single-step technique produces both p-type and n-type doping for future graphene devices 2Single-step technique produces both p-type and n-type doping for future graphene devices 3
(Date:9/17/2014)... affordable health care to reproductive technologies, the justice ... ability of people to identify key issues, articulate ... and find the most defensible ways forward. But ... these societal conversations?, The Hastings Center and the ... have teamed up to publish a series of ...
(Date:9/17/2014)... A UT Arlington engineering professor and his doctoral student ... that can accumulate water collected from fog and dew., ... the world or deserts around the globe., Cheng Luo, ... Xin Heng, PhD candidate in the same College of ... Aug. 25 edition of ACS, (American Chemical Society) ...
(Date:9/17/2014)... "Nature has developed, very cleverly, some lessons on how ... design," said Joseph Shaw, director of the Optical Technology ... and structures at the nanoscale, we,ll discover them." , ... in August during a conference called "The Nature of ... Liang of the University of Arizona College of Optical ...
Breaking Biology News(10 mins):Why bioethics literacy matters 2Why bioethics literacy matters 3Shorebird's beak inspires UT Arlington research on water collection 2Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3
... of Adelaide research has produced a potential new antibiotic ... to antibiotics. The potential new antibiotic targets a ... is a protein inhibitor which binds to the enzyme ... the life cycle of the bacteria. "Existing antibiotics ...
... Boston University School of Medicine (BUSM) and Boston Medical ... provided similar lower back pain relief and reduced the ... lower income minority patients. The results of the study ... back pain could benefit from attending a medically appropriate ...
... together with colleagues at the Denver Police Crime Lab and the ... can arise when a leukocyte (white blood cell) and a cancer ... the journal PLOS ONE , may answer the question of ... to distant organs and tissues of the body the deadly ...
Cached Biology News:Novel chemistry for new class of antibiotic 2
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... systems are high-precision microarrayers capable of ... samples. VersArray ChipWriter Pro systems set ... and reproducibility to deliver unparalleled quality ... Their modular component design and flexible ...
Thermal printer paper is used with the thermal printer for the VersaFluor fluorometry systems. Supplied as 10 rolls....
... Gel extraction kit, 100 preps Storage: The kit ... For longer storage, keep all contents of the ... column purification kit utilizes a silica-gel based membrane ... fragments in the presence of specialized binding buffers. ...
Biology Products: